Identification of p53 dysfunction in MDS, which may be generated independent of TP53 mutations, is crucial for accurate risk assessment and intervention strategies, and for refining the design of ...

Colorectal cancer is the third most diagnosed type of cancer worldwide. Up to 80% of the cases are related to environmental ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y22 ...

May Overcome Resistance to Azacitidine-Venetoclax Regimen and Trigger Apoptosis of TP53 Mutated AML CellsNEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) ...

Enrollment on track in Phase 2 pivotal portion of PYNNACLE clinical trial evaluating rezatapopt as monotherapy in patients with TP53 Y220C and KRAS wild-type advanced solid tumorsInterim analysis from ...

About PMV Pharma PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53. TP53 mutations are found in ...

Work at Scorpion Therapeutics Inc. has led to the identification of cellular tumor antigen p53 (TP53) (Y220C mutant) activators reported to be useful for the treatment of cancer.

Nutshell Therapeutics Inc. has synthesized deuterated indolizine compounds acting as cellular tumor antigen p53 (TP53) (Y220C mutant) reactivators reported to be useful for the treatment of cancer.